Intravenous Solutions Market Size, Share & Trends Analysis Report By Product (TPN, PPN), By Nutrients (Carbohydrates, Vitamins & Minerals, Single-dose Amino Acids) By Region (Asia Pacific, North America), And Segment Forecasts, 2024 - 2030

Intravenous Solutions Market Size & Trends

The global intravenous solutions market size was estimated at USD 12.9 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 8% from 2024 to 2030. The increasing cases of malnutrition and growing geriatric population are anticipated to drive market growth. In addition, growing cases of illnesses, such as cancer, neurological conditions, and gastrointestinal disorders, where intravenous solutions are patients' primary sources of energy, are expected to boost market growth. Furthermore, the market for intravenous (IV) solutions will benefit from the growth in R&D initiatives and rising number of new product launches. The presence of a large geriatric population with low immunity levels & susceptibility to neurological diseases, cardiovascular disorders, cancer, and spinal injuries is likely to remain a high-impact rendering driver of the market.

For instance, according to the World Health Organization, the global population aged 60 years and above is expected to increase from around 1 billion in 2020 to about 1.4 billion in 2030 and will likely almost double to around 2.1 billion by 2050. The number of elderly patients with critical illnesses has significantly increased in the past few years. Thus, demand for the latest surgical treatments that can help increase life span and the need for intensive care & postoperative treatment, including parenteral nutrition products, will increase. Moreover, the high prevalence of preterm births, especially in emerging economies, such as India and China, is expected to drive market growth. According to the WHO, 1 in 10 babies are born preterm, and this is a global concern. Thus, high incidence of preterm births in emerging economies, improved healthcare infrastructure, and growing healthcare expenditure & patient awareness will augment market growth.

Furthermore, according to the WHO, worldwide cancer incidence (cases per year) was nearly 18.1 million in 2018, which is expected to increase to 22.0 million by 2034. The increasing prevalence of gastrointestinal cancer, including esophageal, gastric, liver, colon, and pancreatic cancers, is further anticipated to drive the parenteral nutrition market over the coming years. According to the WHO, 60 to 70 million people in the U.S. are affected by gastrointestinal disorders, boosting the need for parenteral nutritional products that contain glutamine, phospholipids, glucose, and amino acids. Furthermore, a common symptom associated with cancer is anorexia or unintentional weight loss, creating the need for parenteral nutrition due to its effectiveness, boosting market growth.

Product Insights

Based on product, the market is categorized into Total Parenteral Nutrition (TPN) and Peripheral Parenteral Nutrition (PPN). In 2023, the TPN segment dominated the market with a revenue share of 66.3%. Moreover, the segment is expected to register the fastest CAGR of 8.2% from 2024 to 2030. TPN is a comprehensive technique of administering most nutrients via IV technique. In addition, TPN solutions are highly concentrated than PPN solutions and are used predominantly in Surgical Intensive Care Units (ICU). According to the Society of Critical Care Medicine, more than 5 million patients are admitted annually to ICUs within the U.S.

The Peripheral Parenteral Nutrition (PPN) segment is expected to experience significant growth rate of 7.5% from 2024 to 2030. According to MDPI, various benefits were observed in colorectal surgery patients undergoing early PPN. PPN supplementation and adherence to Enhanced Recovery after Surgery (ERAS) programs can reduce postoperative complications. Moreover, the patients receiving PPN had a lower risk of complications than those receiving conventional fluid therapy. PPN also decreases the likelihood of complications worsening or major complications developing.

Nutrients Insights

Based on nutrients, the global market is categorized into carbohydrates, single-dose amino acid solutions, vitamins & minerals, parenteral lipid emulsion, and others. The single-dose amino acid solution segment dominated the market with a revenue share of 31.6% in 2023. Different studies have stated that single-dose amino acids provide a complete protein source, are customizable with other parenteral formulations, and can be easily administered.

The vitamins and minerals segment is expected to register a CAGR of 9.7% from 2024 to 2030. Vitamins are vital for blood clotting, RBC formation, and maintaining mucus membranes. Deficiencies lead to anemia, beriberi, pellagra, and chronic mental conditions. Treatment involves parenteral or enteral nutrition. Minerals are essential organic chemicals that regulate metabolic pathways, including β-carotene, sodium chloride, magnesium, potassium, and phosphorous. Deficiency weakens the immune system & bones and causes fatigue due to poor mineral absorption. PN can be used for treatment in such cases.

Regional Insights

In 2023, North America dominated the global market with a share of 41.0% due to the presence of key players, favorable rules & regulations, and strong reimbursement structure in countries, such as the U.S. For instance, in 2022, Assure Infusions, Inc. announced an investment of USD 20 million to construct a state-of-the-art manufacturing facility in Bartow, Florida, to produce IV solutions. The company aims to mitigate the demand-supply gap for IV solutions in the U.S.

Asia Pacific is anticipated to witness a robust growth at a CAGR of 9.0% from 2024 to 2030. The rising prevalence of chronic diseases due to unhealthy eating habits and high demand for cost-effective care treatment are some of the factors expected to drive market growth. According to a UNICEF article in 2021, more than 375.8 million people were undernourished in Asia Pacific in 2020, which was nearly 54 million more than that in 2019.

Key Companies & Market Share Insights

New product developments, geographic expansions, acquisitions, and collaborations are the key strategic undertakings influencing the industry dynamics. For instance, in June 2023, Vifor Pharma received FDA approval for Injectafer. Injectafer is the only IV replacement therapy for adult patients suffering from heart failure & iron deficiency.

Intravenous Solutions Market Report Scope

Global Intravenous (IV) Solutions Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global intravenous solutions market report based on product, nutrients, and region:

• Product Outlook (Volume, Thousand Units; Revenue, USD Million, 2018 - 2030)

  • Total Parenteral Nutrition

  • Peripheral Parenteral Nutrition

• Nutrients Outlook (Volume, Thousand Units; Revenue, USD Million, 2018 - 2030)

  • Carbohydrates

  • Vitamins & Minerals

  • Single-dose Amino Acids

  • Parenteral Lipid Emulsion

  • Others

• Regional Scope Outlook (Volume, Thousand Units; Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait